

RESEARCH ARTICLE

Selected serum microRNA, abdominal aortic calcification and risk of osteoporotic fracture

Marie-Eva Pickering^{1,2*}, Marjorie Millet², Jean-Charles Rousseau², Martine Croset², Pawel Szulc², Olivier Borel², Elisabeth Sornay Rendu², Roland Chapurlat^{1,2}

1 Service de Rhumatologie et Pathologie Osseuse, Hôpital E Herriot, HCL, Lyon, France, **2** Inserm UMR 1033, Lyon, France

* marie-eva.pickering@hotmail.fr



Abstract

Context

MicroRNA (miRNA) regulate post-transcriptionally the expression of osteogenesis and angiogenesis associated genes and emerge as potential non-invasive biomarkers in vascular and bone diseases. Severe abdominal aortic calcification (AAC) is associated with higher risk of cardiovascular event and of fragility fracture.

Objective

To identify miRNA linked to the aggravation of AAC and to incident osteoporotic fracture.

Design

Postmenopausal women (>50 years) with available serum at inclusion and data for each outcome (Kauppila score and incident fracture) were selected from the OFELY prospective cohort. We conducted a case-control study in 434 age-matched women, 50% with incident osteoporotic fracture over 20 years of follow-up and a second study in 183 women to explore AAC over 17 years.

Methods

Serum expression of three miRNA involved in vascular calcification and bone turnover regulation (miR-26a-5p, -34a-5p, and -223-5p) was quantified at baseline by TaqMan Advanced miRNA technology and expressed by relative quantification. Outcomes were the association of miRNA levels with (1) incident osteoporotic fractures during 20 years, (2) AAC aggravation during 17 years.

Results

MiRNA level was not associated with incident fractures (miR-26a-5p: 1.06 vs 0.99, $p = 0.07$; miR-34a-5p: 1.15 vs 1.26, $p = 0.35$; miR-223a-5p: 1.01 vs 1.05, $p = 0.32$). 93 women had an increase in Kauppila score over 17 years while 90 did not. None of the miRNAs was associated with an aggravation in AAC (miR-26a-5p: 1.09 vs 1.10, $p = 0.95$; miR-34a-5p: 0.78 vs 0.73, $p = 0.90$; miR-223-5p: 0.97 vs 0.78, $p = 0.11$).

OPEN ACCESS

Citation: Pickering M-E, Millet M, Rousseau J-C, Croset M, Szulc P, Borel O, et al. (2019) Selected serum microRNA, abdominal aortic calcification and risk of osteoporotic fracture. *PLoS ONE* 14(5): e0216947. <https://doi.org/10.1371/journal.pone.0216947>

Editor: Dominique Heymann, Universite de Nantes, FRANCE

Received: December 31, 2018

Accepted: May 1, 2019

Published: May 14, 2019

Copyright: © 2019 Pickering et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript.

Funding: The authors received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.

Abbreviations: AAC, Abdominal Aortic Calcification; AP, Alkaline Phosphatase; BMD, Bone Mineral Density; BMP/SMAD1, Bone Morphogenetic Protein/ SMAD1; BMI, Body Mass

Index; cDNA, Complementary Deoxyribonucleic Acid; C_T, Cycle Threshold; CTGF, Connective Tissue Growth Factor; CTX-I, Carboxy-terminal Cross-linking Telopeptide of Type I Collagen; DXA, Dual Energy X-ray Absorptiometry; GFR (MDRD), Glomerular Filtration Rate (Modification of Diet in Renal Disease); ICC, Intraclass Correlation Coefficient; JAG-1, Jagged 1; miRs, miRNAs, microRNAs; NFATc 1, Nuclear Factor of Activated T-cells, cytoplasmic 1; NFIA, Nuclear Factor I A; OFELY, Os des Femmes de Lyon; OPG, Osteoprotegerin; OR, Odds Ratio; PCR, Polymerase Chain Reaction; PINP, Procollagen Type I amino-terminal Propeptide; PNUITS, PP1 Nuclear Targeting Subunit; PTH, Parathormone; RANKL, Receptor Activator of Nuclear Factor- κ B; RNAs, Ribonucleic Acid; RT, Reverse Transcription; SD, Standard Deviation; Tgjf2, Thymine Guanine-Interacting Factor 2; VFA, Vertebral Fracture Assessment.

Conclusions

Circulating miR-26a-5p, -34a-5p and -223-5p are not significantly associated with incident fracture and AAC aggravation.

Introduction

Although osteoporosis and cardiovascular disease are traditionally viewed as separate disease entities, increased cardiovascular risk is significantly associated with the risk of fragility fracture in hips and vertebrae [1–3]. Both conditions share an increase in prevalence with aging and other risk factors such as menopause, smoking, alcohol consumption and low physical activity [4,5].

Abdominal aortic calcification (AAC) is assessed by semi-quantitative score on spine radiographs and spine scans obtained by Dual-Energy X-ray Absorptiometry (DXA). Severe AAC is associated with a higher risk of major cardiovascular event [5–9]. The fine regulation of arterial vessel calcification involves hormones, cytokines, calcium deposit, other bone remodeling factors, and the differentiation of vascular smooth muscle cells to osteoblast-like cells [6–10]. Severe AAC reflecting poor cardiovascular health status and disturbed blood flow in the vascular system is also associated with lower bone mineral density (BMD), faster bone loss and a higher risk of major fragility fracture [11–14]. This fracture risk remains increased after adjustment for BMD and other potential risk factors. Severe AAC is also related to increase in vertebral fracture in older men [15].

Biological factors such as bone morphogenetic proteins, osteoprotegerin, receptor activator of nuclear factor κ B ligand, parathyroid hormone, phosphate, oxidized lipids and vitamins D and K are altered in both diseases [16]. A better knowledge of the mechanisms underlying the association between AAC and fracture risk would lead to the identification of biological markers in individuals who are both at higher risk of cardiovascular event and osteoporotic fracture.

MicroRNAs (miRNAs) are small endogenous regulatory RNAs that influence many physiological and pathophysiological processes by acting as epigenetic key actors in the regulation of gene expression [17]. Numerous studies have reported the miRNA-mediated regulation of bone development and homeostasis through their activity in osteoblastogenesis and osteoclastogenesis [18,19]. Some specific miRNAs that are actors in bone micro-architecture and fragility are also involved in the pathogenesis of cardiovascular diseases, including angiogenesis and the vascular calcification process [20–23]. Thus, miRNAs may regulate bone disease (osteoporosis) and vascular calcification, two processes that share some pathogenetic mechanisms. Furthermore, the level of circulating miRNAs in biofluids would reflect the alteration in the patient tissues. In osteoporotic patients, miRNA level in serum has been associated to alterations of bone metabolism, decreased bone mass and risk of fractures [24,25]. Circulating miRNAs appear as promising non-invasive biomarkers [26]. In regard to their short length and association with proteins and exosomes, miRNAs resist to RNase digestion and to multiple freeze-thaw cycles and present elevated stability in frozen samples across the years [27].

We conducted the study to clarify the link between cardiovascular risk and osteoporosis in a well-characterized cohort of women and to find a common determinant to these two pathologies. Cardiovascular risk and osteoporosis are assessed by factors easy to use in clinical practice. The purpose of this study was to find out whether the levels of specific circulating miRNAs might provide information on the cardiovascular risk, evaluated with CAA, and the

incidence of osteoporotic fracture in postmenopausal women over 20 years of follow-up. Three miRNAs (miRs-26a-5p, 34a-5p, and 223-5p) have been selected for their previously reported activity on both the cardiovascular and bone systems. Their potential association with the progression of AAC and the risk of fractures has been investigated by analyzing miRNA concentrations in the serum of patients from a nested case-control analysis of the prospective OFELY cohort.

Material and methods

Study design and subjects

We conducted two studies in women from the OFELY cohort (Fig 1). The OFELY cohort (Os des Femmes de LYon) is an ongoing prospective study of the determinants of bone loss [28]. It included 31–89 year-old women, recruited between February 1992 and December 1993, and randomly selected from the affiliates of a French health insurance company (Mutuelle Générale de l'Education Nationale) with an annual follow-up. Available blood samples at inclusion, radiographic scores of AAC at inclusion and at year 17 and the knowledge of incident fractures in the course of 20 years were selection criteria of these post-menopausal women.

To study the association between miRNA expression and incident osteoporotic fracture, we conducted a case control analysis with 217 women with incident fragility fracture and 217 age-matched women without incident fragility fracture over 20 years. To study the link between miRNA expression and the progression of AAC, we conducted an analysis among the 183 women with available data of AAC over 17 years. Written informed consent was obtained from each participant and the study was approved by the local ethics committee (Comité de Protection des Personnes Sud-Est II).

Clinical parameters

Women completed a written health questionnaire at baseline, including medical history, tobacco use, medication use, fall(s) in the course of the past 12 months, and occurrence of radiologically confirmed low-trauma fractures [29]. Height and weight were measured and body mass index (BMI) was calculated (kg/m²).

Moreover, bone mineral density (BMD) was measured by DXA with a QDR 2000 device (Hologic, Waltham, MA, USA) at the lumbar spine and the total hip at baseline. The T-score was calculated from the HOLOGIC France references values.

Blood sample collection and biochemical measurements

Blood samples were collected between 8:00 and 9:30 a.m. after an overnight fast. Serums were aliquoted in 1mL tubes and then stored frozen at –80°C until assayed. The macroscopical analysis at time of blood sampling assessed for serum quality with none of the serum affected by haemolysis. Only two serums had fibrin at time of extraction. At inclusion time, a number of parameters were measured in morning fasting blood samples including, Osteocalcin (ng/ml), N-terminal propeptide of type I collagen (PINP) (ng/ml), Bone alkaline phosphatase (BAP) (ng/ml), C-telopeptide of type I collagen (sCTX-I) (ng/ml), Calcium (mg/l), Phosphate (mg/l), Creatinine (mg/l), globular filtration rate (GFR MDRD) (ml/min/1.73m²), 25-hydroxycholecalciferol (25-OH Vitamin D) (ng/ml) and parathyroid hormone (PTH) (pg/ml). The bone turnover markers (Osteocalcin (ng/ml), PINP (ng/ml) and sCTX-I (ng/ml)) were measured in serum by automated tests (Elecsys N-MID osteocalcin, Elecsys PINP and Elecsys b-Crosslaps, respectively; Roche Diagnosis, Meylan, France). BAP (ng/ml) was measured by Elisa (Metra BAP EIA kit, Quidel Corporation, USA). Creatinine was measured, and GFR MDRD was




Fig 1. Study design.

<https://doi.org/10.1371/journal.pone.0216947.g001>

calculated using a modified kinetic method and the Chronic Kidney Disease Epidemiology Collaboration, respectively [30]. 25-OH Vitamin D (ng/ml) was assessed by radioimmunoassay (DiaSorin, Stillwater, USA) after acetonitrile extraction. PTH (pg/ml) was measured using a human specific two-site immunochemiluminescence assay (ELECSYS, Roche, Indianapolis, IN, USA). Calcium (mg/l) and Phosphate (mg/l) were measured by colorimetric assay.

Fracture evaluation

Incident non-vertebral and clinical vertebral fragility fractures, all confirmed by radiographs or surgical report were reported at every annual follow-up. For women who did not come to the Clinic for their annual evaluation, a letter was sent annually to identify the occurrence of any fracture. Only low trauma fractures (i.e., those occurring as a result of falls from standing height or less) were taken into account in this analysis, and we excluded fractures of fingers, toes, skull, and face. Vertebral fractures were also assessed in women aged 50 years and over at the inclusion in the study confirmed on lateral X-ray films of thoracic and lumbar spine at baseline and every 4 years, and after 19 years on DXA (Hologic Discovery, HOLOGIC Inc; Bedford, MA) using Vertebral Fracture Assessment software (VFA). They were identified with the semiquantitative method of Genant et al [31] by a trained physician (ESR).

Assessment of abdominal aortic calcification

AAC were measured on lateral spine radiographs using the Kauppila score. The Kauppila score is a 24-point semi quantitative score, used to quantify the presence and severity of AAC. Calcifications are scored (0 to 3 points) on the 8 segments of the aortic abdominal wall according to their length, and these scores are summed to obtain a 24-point score [32].

The score was evaluated at inclusion and after 17 years of follow-up by a single reader (MEP). Reproducibility was assessed using 30 radiographs and calculated using the intraclass correlation coefficient (ICC). The intra-reader reproducibility was excellent (ICC = 0.968, IC 95% [0.935–0.984]). The inter-reader agreement was assessed, with a reader (PS) trained to AAC for Kauppila scoring. It was also excellent (for the 1st scores ICC = 0.967, 95%CI: 0.933–0.984 and for the 2nd scores ICC = 0.953, 95%CI 0.906–0.977).

A methodology of missing Kauppila score data was established. As AAC do not decalcify, unavailable data were replaced by “0” if the Kauppila score at subsequent follow-up was 0. Data were considered unavailable if the radiographs were missing or low quality. Radiographs were considered of good quality if the X-ray projection was the one expected (lateral lumbar spine radiograph), if the lower endplate of T12 and the superior endplate of S1 were viewable, and if the distance in front of the anterior vertebral wall was sufficient. In the absence of AAC, this distance was considered sufficient if the measure was at least of 2.5 cm from the middle of the vertebral body, for an anteroposterior length of the vertebral body of 4 cm. In the presence of AAC, radiographs were considered of low quality if the anterior vascular wall was not visible in its entirety from L1 to L5.

An increase of >1 point in Kauppila score (Δ Kauppila >1) was retained to define AAC aggravation over 17 years.

Quantification of circulating miRNAs

Preselection of miRNAs. To identify candidate miRNAs linked with increased risk of AAC aggravation and incident osteoporotic fracture, a first miRNA selection was done by computational prediction of their target genes using TargetScan and from experimentally validated target genes using MiRWalk database. From this, three miRNAs (miRs-26a-5p, 34a-5p, and 223-5p) were selected based on their known regulatory functions in vascular calcification

Table 1. Potential activity of candidate microRNAs in bone-related disease and aortic calcification.

MiRs	Target gene* (nucleotide site in 3'UTR)	Regulatory function	In vitro and animal study	Clinical relevance	Ref
miR-26a-5p	-CTGF (38–44; 7 merA1) -BMP/SMAD1 (46–53; 8mer) (103–109; 7merA1)	↓ in vascular diseases angiogenesis, myocardial infarct size and improve heart function ↓ osteoclastic differentiation	↓ in rat cardiac hypertrophy ↓ vascular smooth muscle cell calcification ↓ calcification related-genes (BMP2, SMAD1,2, ALP)	↓ in aortic valve calcification and stenosis	[33–37]
miR-34a-5p	-PPP1R10 (822–828; 7–8 mer) -TGIF2 (90–97; 8 mer) -JAG1 (1302–1308; 7–8 mer)	↑ Age-induced cardiac cell death ↓ Osteoclastogenesis ↓ osteoblast differentiation	↑ cardiac dysfunction after myocardial infarction ↓ bone resorption, bone mass ↓ in vivo bone formation of human stromal stem cells.	Antagomir therapeutic improves aging cardiac dysfunctions and stimulates osteoblast differentiation Attenuates osteoporosis ↓ Therapeutic strategy for enhancing bone formation	[38–41]
miR-223	-SCARB1 (575–582; 8 mer) -FCGR1A (141–147; 7–8 mer) -NFIA (811–818; 8 mer)	↓ HDL-cholesterol uptake, biosynthesis, cholesterol efflux ↓ proliferation and ↑ apoptosis in vascular wall ↑ Inorganic Phosphate-induced-osteoclastogenesis and osteoclast differentiation	↑ HDL-cholesterol, hepatic and total plasma cholesterol in KD mice ↑ in serum and atherosclerotic vascular walls ↓ atherosclerotic lesions in mice ↓ levels in serum, blood cells of chimeric-KD-mice Modulate the balance osteoblast-like/ osteoclast-like	Biomarker for altered cholesterol homeostasis ↑ levels in serum from Kawasaki disease ↓ in serum from patients with chronic kidney disease Treatment to reverse vascular calcification without altering bone structure in CKD-MBD Provide new therapeutic target for atherogenesis	[42–47]

*: The target genes are indicated with the nucleotide position of the seed region in the 3'-UTR (according to Target Scan). ↑ ↓ are for up- and -down regulation respectively.

<https://doi.org/10.1371/journal.pone.0216947.t001>

and bone metabolism and on previously reported experimental animal research and clinical trials (Table 1).

MiRNA quantification. Total RNA was extracted from 200µl serum with the miRCURY Biofluids extraction kit of (Exiqon) according to manufacturer recommendations. Samples were thawed on ice and centrifuged at 3,000g for 5 minutes. A lysis buffer solution containing 1µl of glycogen as RNA carrier and a synthetic spike-in control RNA (cel-miR-39-3p) as internal control was added to the serum. After cellular lysis and protein precipitation, supernatant was placed on a silica micro-column and treated with rDNAse. RNA was eluted with 40 µl RNase/DNAse-free water (Invitrogen) and stored at -80°C.

MiRNAs were quantified by TaqMan Advanced miRNA technology (Applied Biosystems, ThermoFisher Scientific). The first analytical step consists of the universal reverse transcription (RT) to prepare cDNA from 2µl of total RNA using a TaqMan Advanced miRNA cDNA synthesis kit. Briefly, the kit uses 3' poly-A tailing and 5' ligation of an adaptor sequence for each end extension of the mature miRNAs present in the sample, prior to RT. Universal RT primers anneal to the universal sequences present on both the 5' and 3' extended ends of the mature miRNAs. Quantification of miRNAs expressed at low copy number was improved by 14 cycles of cDNA amplification in a 2X TaqMan PreAmp master mix containing Megaplex PreAmp primers.

The qPCR amplification was performed on 1:10 dilution of cDNA obtained by miR-Amp reaction on 5 µl of the RT reaction, using the 2X Fast Advanced Master Mix and the 20X TaqMan Advanced miRNA Assays. These TaqMan Advanced miRNA assays (Table 2) contain pre-formulated primers and TaqMan MGB (minor groove binder) probes that allow the recording of fluorescence signal in the PCR reaction. The MicroAmp Fast Optical 96-Well Reaction Plates (ThermoFisher) were designed for the quantification in duplicate of seven miRNAs on the QuantStudio 7 flex (Applied Biosystems) according to the manufacturer's

Table 2. Identification of the candidate microRNAs, of the three endogenous normalizer microRNA used and of the spike quality control of the analysis.

miR Base ID	NCBI Accession Number	TaqMan Advanced miRNA Assay (ID)	Sequence of the mature miRNA 5'-----3'
hsa-miR-26a-5p	MIMAT0000082	477995_mir	UUCAAGUAAUCCAGGAUAGGCU
hsa-miR-223-5p	MIMAT0004570	477984_mir	CGUGUAUUUGACAAGCUGAGUU
hsa-miR-34a-5p	MIMAT0000255	rno481304_mir	UGGCAGUGUCUUAGCUGGUUGU
hsa-miR-191-5p	MIMAT0000440	477952_mir	CAACGGAAUCCCAAAGCAGCUG
hsa-miR-222-3p	MIMAT0000279	477982_mir	AGCUACAUCUGGCUACUGGGU
hsa-miR-361-5p	MI0000760	481127_mir	UUAUCAGAAUCUCCAGGGGUAC
cel-miR-39-3p	MI0000010	478293_mir	UCACCGGGUGUAAAUCAGCUUG

All the nomenclature is according to miRBase V21 and the TaqMan Advanced miRNA Assays are from Applied Biosystems.

<https://doi.org/10.1371/journal.pone.0216947.t002>

protocol. The C_T (threshold cycle value) was recorded as the cycle number at which the fluorescence generated within a reaction crosses the fluorescence threshold, a fluorescent signal significantly above the ROX fluorescence background recorded in each sample [48].

The miRNA level was expressed by relative quantification according the following formula: Relative quantification = $2^{-\Delta\Delta C_T}$, with $\Delta C_T = (C_T \text{ miRNA} - C_T \text{ mean of the 3 endogenous controls})$ and $\Delta\Delta C_T = (\Delta C_T \text{ of the miRNA} - \Delta C_T \text{ mean of the miRNA through all samples})$. Data were normalized with the mean of expression level of three endogenous miRNAs: hsa-miR-191-5p, hsa-miR-222-3p and hsa-miR-361-5p, that are known to be ubiquitously expressed and without reported impact on cardiovascular diseases or bone. The exogenous spike cel-miR-39-3p was used as a qPCR quality control (Table 2).

Statistics. The baseline characteristics of the women are presented as mean \pm SD for continuous variables and proportion of patients (%) for categorical variables. Chi-squared tests and Wilcoxon tests were used to compare women with and without incident fracture. In order to identify the association between miRNAs and the risk of incident fracture or the aggravation in Kauppila score, we performed a logistic regression using quartiles of relative quantification for each miRNA.

All results are expressed in median [interval interquartile] or mean \pm SD. All statistical analyses were performed using Stata 12 (StataCorp LP, College Station, Texas, USA).

Results

Clinical characteristics

In the first study, we have selected the 217 women who had incident fragility fracture over 20 years of follow-up and age-matched them with a random sample of non fractured women (63 [57–72] years old). Fractured women were significantly thinner than controls (body weight = 59.2 [52.8–64.4] vs 60.6 [54.6–67.6] kg, $p = 0.04$; and BMI = 23.2 [21.3–25.5] vs 24.2 [22–27.2] kg/cm^2 , $p = 0.006$) (Table 3).

In the second study, 183 women were included to examine the link between the aggravation in AAC and the miRNA expression, 93 with and 90 without an aggravation in Kauppila score during the 17 years of follow-up (respectively 58 [55–61] and 55 [53–58] years old, respectively). Weight and BMI were not significantly different between both groups (Table 4).

Associations between miRNA expression and incident fracture

Levels of miR-26a-5p, miR-34a-5p and miR-223-5p in patient serum were not significantly different between women with or without incident fracture (Table 3).

Table 3. Baseline demographic and biological characteristics of cases (with incident fracture) versus controls (without incident fracture), and miRNA quantification (median [interval interquartile]).

	Cases (n = 217)	Controls (n = 217)	P values
Age (years)	63 [57–72]	63 [57–72]	0.93
Weight (kg)	59.2[52.8–64.4]	60.6 [54.6–67.6]	0.04
Height (cm)	158 [154–162]	158 [154–162]	0.50
BMI (kg/m ²)	23.2 [21.3–25.5]	24.2 [22–27.2]	0.006
Total Hip T-score	-1.7 [-2.3- -1.0]	-1.16 [-2.0- -0.3]	<0.0001
Lumbar Spine T-score	-1.9 [-2.6- -1.1]	-1.0 [-1.8- -0.3]	<0.0001
Smokers, n(%)	17 (8)	14 (6)	0.58
Fallers in the past year, n(%)	75 (35)	88(41)	0.20
Prior Fx, n(%)	32(15)	44(20)	0.13
Osteoporosis treatments, n(%) ^a	36(17)	39(18)	0.70
Comorbidity, n(%) ^b	50(23)	42(19)	0.35
Cardiovascular diseases, n(%)	45(21)	39(18)	0.47
Osteocalcin (ng/ml)	12.7 [10.2–16.2]	12.1 [10.0–15.6]	0.29
PINP (ng/ml)	45.7 [34.6–60.5]	45.1[33.0–64.1]	0.88
Bone BAP (ng/ml)	11.8 [9.4–14.7]	12.2 [9.6–15.0]	0.33
sCTX-I (ng/ml)	0.51 [0.3–0.6]	0.46 [0.3–0.7]	0.27
Calcium (mg/l)	93 [91–95]	93 [91–95]	0.20
Phosphate (mg/l)	34 [32–37]	34 [32–37]	0.28
Creatinine (mg/l)	9.4 [8.5–10.2]	9.3 [8.7–10.3]	0.78
GFR (MDRD) (ml/min/1.73m ²)	63.9 [58.2–71.9]	64.2 [58.0–71.1]	0.82
25-OH Vitamin D (ng/ml)	32 [23–41]	34.5 [23.5–45.5]	0.24
PTH (pg/ml)	31.6 [23.1–39.3]	29.8 [24.2–39.8]	0.84
miRNA (Relative quantification)			
miR-26a-5p	1.06 [0.85–1.27]	0.99 [0.85–1.17]	0.07
miR-34a-5p	1.15 [0.53–1.87]	1.26 [0.60–2.07]	0.35
miR-223-5p	1.01 [0.68–1.43]	1.05 [0.72–1.56]	0.32

^a hormonal replacement therapy

^b Diabetes mellitus, thyroid or parathyroid disorders, renal insufficiency, rheumatoid arthritis, gastric or intestinal surgery, malignancy and stroke

<https://doi.org/10.1371/journal.pone.0216947.t003>

The increase in one quartile of miRNA quantification was not associated with the risk of incident fracture, with or without adjustment for BMI and Total Hip BMD (adjusted OR (95%CI) for miR-26a-5p: 1.18 (0.99–1.41); miR-34a-5p: 0.88 (0.73–1.05); miR-223-5p: 0.98 (0.82–1.17)).

Associations between miRNA expression and aggravation of AAC

The Kauppila score increased from 0 [0–0] to 2 [0–5] over 17 years.

Women with AAC aggravation were significantly older, by about 3 years (p<0.0001). MiR-26a-5p, miR-34a-5p and miR-223-3p were not significantly linked to the aggravation in AAC (Table 4). The increase in one quartile of miRNA quantification was not associated with AAC aggravation, with or without adjustment for age and Kauppila score at baseline (adjusted OR (95% CI) for miR-26a-5p: 0.93(0.69–1.27); miR-34a-5p: 0.97 (0.71–1.34); miR-223-5p: 1.13(0.81–1.57)).

Discussion

This analysis from the OFELY cohort showed that the serum concentrations of three microRNAs involved both in the regulation of bone turnover and vascular calcification were not significantly associated with incident fractures and progression of AAC.

Table 4. Baseline demographic and biological characteristics of 183 women with versus without an aggravation in Kauppila score during 17 years of follow-up (median [interval interquartile]) and miRNA quantification (median [interval interquartile]).

	Aggravation in Kauppila score (n = 93)	No aggravation in Kauppila score (n = 90)	P value
Age (years)	58 [55–61]	55 [53–58]	<0.0001
Weight (kg)	56.8 [51.4–63.6]	56.6 [52.2–60.6]	0.79
Height (cm)	158 [156–162]	160 [156–163]	0.23
BMI (kg/m ²)	22.5 [20.9–24.9]	22.3 [20.9–23.7]	0.36
Total Hip Tscore	-1.2 [-1.9- -0.5]	-1.1 [-1.6- -0.4]	0.47
Lumbar Spine Tscore	-1.5 [-2.4- -1.1]	-1.5 [-2.1- -0.2]	0.27
Smokers, n(%)	8(9)	3(3)	0.13
Fallers in the past year, n(%)	25(27)	21 (23)	0.58
Prior Fracture, n(%)	2(2)	1(1)	0.58
Osteoporosis treatments, n(%) ^a	26(28)	33(37)	0.21
Comorbidity ^b , n(%)	20(19)	22(23)	0.77
Cardiovascular diseases, n(%)	9(10)	5(6)	0.29
Initial Kauppila score >0, n(%)	36 (39)	6(7)	<0.0001
Osteocalcin (ng/ml)	11.8 [10.1–14.8]	12.6 [9.5–15.8]	0.41
PINP (ng/ml)	46.4 [35.9–57.3]	46.7[35.6–62.4]	0.49
Bone AP (ng/ml)	11.8 [8.7–13.9]	11.7 [10.0–14.4]	0.53
sCTX-I (ng/ml)	0.51 [0.3–0.7]	0.52 [0.3–0.6]	0.78
Calcium (mg/l)	93 [91–95]	93 [91–95]	0.28
Phosphate (mg/l)	35 [32–37]	33 [31–37]	0.25
Creatinine (mg/l)	9.2 [8.5–10.1]	9.3 [8.6–9.8]	0.57
GFR (MDRD) (ml/min/1.73m ²)	66.7 [59.5–72.5]	66.8 [61.3–72.6]	0.36
25-OH Vitamin D (ng/ml)	38 [28–47]	38 [29–45]	0.81
PTH (pg/ml)	28.1 [23.1–37.8]	28.6 [22.7–35.4]	0.65
miRNA (Relative quantification)			
miR-26a-5p	1.09 [0.94–1.28]	1.10 [0.89–1.30]	0.95
miR-34a-5p	0.78 [0.46–1.21]	0.73 [0.38–1.50]	0.90
miR-223-5p	0.97 [0.69–1.22]	0.78 [0.56–1.22]	0.11

^a hormonal replacement therapy

^bDiabetes mellitus, thyroid or parathyroid disorders, renal insufficiency, rheumatoid arthritis, gastric or intestinal surgery, malignancy and stroke

<https://doi.org/10.1371/journal.pone.0216947.t004>

Studies from our group [3,15,49] and others [11–14,50] have previously demonstrated the association of AAC with bone fragility, two processes that share common pathogenetic mechanisms in men and women from various populations, especially in the elderly [51,52]. More specifically, in postmenopausal women, the aggravation in AAC score is linked to the increase in bone resorption in particular when BMD is inversely linked to AAC score [5,12,13]. The connection of AAC with poor bone status, higher risk of fracture and bone loss has been consistently reported in cohorts after adjustment for numerous shared risk factors, mainly age, lifestyle, co-morbidity, hormones, vitamin D status and medications that influence both pathologies [53]. For example, severe AACs are linked to a greater prevalence of vertebral fracture after adjustment for age and BMI, and a greater number of vertebral fractures has been shown in older men, after adjustment for BMD and other variables [15].

Epigenetic factors interfere with the “calcic paradox”, a common determinant of AAC and bone fragility where cardiac valves calcify and bone decalcifies. At the transcriptomic level, the calcification of the aortic media is regulated by calcium deposal, inorganic phosphate and bone-related factors. In this study we looked for epigenetic factor as a single assessment of

AAC and fracture risk that could identify patients for prevention and treatment of cardiovascular and bone disorders. Therefore, we have designed the study to assess the risk factors that are shared by both conditions. Two groups of patients have been selected in the well-characterized OFELY cohort: a sizeable control sample of women differing significantly only for incident fracture and a second group of women with available data to explore AAC over 17 years of follow-up. Secondly, we used miRNA level in serum as an easily accessible epigenetic marker to assess the dysregulation of gene expression in both diseases.

Aberrant miRNA signaling alters bone homeostasis and contributes to the progression of bone disorders. Among these, miR-26a-5p, 34a-5p, 125b-5p, 145-5p, 146a-5p, 221-5p and 223-5p regulate the transformation of smooth muscle to vascular cells and participate to calcification by interacting with osteoblasts and osteoclasts [22,23,33,34]. Therefore, based on their mRNA targets, known regulatory function and clinical relevance, we have selected miR-34a-5p, miR-26a-5p and miR-223-5p as common potential biomarkers of these diseases.

MiR-26a-5p is known to alter pathological angiogenesis by targeting BMP/SMAD 1 signaling (bone morphogenic protein/SMAD1) [35] and impaired angiogenesis in diabetic dermal wound healing [36]. Administration of miR-26a-5p inhibitor to mice increases SMAD1 expression, induces angiogenesis, reduces myocardial infarct size, and improves heart function [37]. Aortic stenosis decreased miR-26a-5p expression in patients undergoing aortic valve replacement compared to those with aortic insufficiency, suggesting a decrease in valvular aortic calcification. Although the impact of miR-26a-5p on bone itself is poorly reported, CTGF expression and BMP/SMAD1 pathway are involved in osteoclastic differentiation and these pathways also impact on osteoblastogenesis [19,35]. *In vitro*, miR-26a-5p inhibited vascular smooth muscle cell calcification by regulating the expression of CTGF, OPG, RANKL and ALP [34]. MiR-34 family has been consistently reported to interfere with cellular regulation of bone homeostasis. MiR-34a decreased osteoclastic differentiation by targeting several pathways including NFATc1 or Tgif2 [38]. Transgenic mice overexpressing miR-34a had a lower bone resorption and higher bone mass while miR-34a knock out in mice showed higher bone resorption and reduced bone mass. Other studies, in triple knock-out mice for miR-34a, b and c confirmed that the loss of function of miR-34 induces higher bone resorption [39]. The overexpression of miR-34a inhibited osteoblastic differentiation of human stromal stem cells, and conversely, *in vivo* bone formation was increased in case of miR-34a deficient human stromal stem cells [40], with JAG-1, a ligand for Notch 1 as a potential target of miR-34. By inhibiting osteoblast differentiation and *in vivo* bone formation, miR-34a is a major actor of the calcic paradox. However, on the cardiac site, age is a crucial determinant of miR-34a activity since cardiac expression of miR-34a increases with age in mice. MiR-34a deficient mice had lower age-induced apoptosis of cardiomyocytes and a better cardiac function [41] and miR-34a inhibition was linked to lower cell death and fibrosis after acute myocardial infarction, with improvement of myocardial function recovery. One of the pathways suggested is PNUTS (protein phosphatase 1 (PP1) nuclear targeting subunit) also known as PPP1R10, with a reduction of telomere shortening and age-associated DNA damage responses [41]. In our study we found abundant levels of the miR-223 mature forms in serum, of the initially described miR-223* (-3p) and of its hairpin counterpart, miR-223-5p. This high miRNA expression would improve the specificity and reproducibility of their measurement in serum. This increased the potential of miR-223, that has been associated to inflammation, atherogenesis, vascular calcification, cardiovascular and bone disease, to be a biomarker in these pathologies [33,42,43]. The genetic ablation of miR-223 in mice increased HDL-cholesterol and plasma total cholesterol by coordinating transcriptional control of several genes in lipoprotein and cholesterol metabolism [44]. MiR-223 expressed in bone marrow-derived blood cells is secreted in serum and enters the endothelial and vascular smooth muscle cells to act as an endocrine genetic signal in

vascular injury. It may provide a novel mechanism for vascular complication in Kawasaki disease [45]. Although the role of miR-223 in osteoclastogenesis is controversial, its expression is affected during osteoclastogenesis [46]. Inorganic phosphate decreased the miR-223 level and osteoclastogenesis by affecting the expression of NFIA and RhoB in human osteoclasts and calcifying vascular smooth muscle cells. In chronic kidney disease, miR-223 increased in serum patients, reflecting changes of bone and calcification pathways [47].

Circulating miR-26a-5p, miR-34a-5p and miR-223-5p were not significantly different between women with or without incident fracture. A difference in the clinical characteristics of our cohort might explain the discrepancy between these results and previous studies [3,25,54,55]. Here, the study was designed to include 434 age-matched women with and without fractures during the 20 years of follow-up and to eliminate the confounding factors that may not be related to the miRNA influence in the two pathologies. The level of serum miRNA is associated with aging in a wide range of physiological processes and diseases including sarcopenia [55]. In our first study, cases and controls do not differ by parameters such as bone markers, calcium, phosphate, PTH and 25-OH vitamin D. The two groups differed significantly in BMI and weight but the associations were the same after BMI-adjustment. We hypothesize that biomarker studies associating circulating miRNA levels to bone fragility and fractures that are reported in smaller sample sizes of patients did not exclude some of these confounding factors.

Circulating miR-26a-5p, miR-34a-5p and miR-223-5p were not significantly linked to AAC aggravation over 17 years and age-adjusted OR was not significant either. None of these miRNAs was associated to the aggravation of Kauppila score in comparable size samples of women that experienced similar comorbidity, cardiovascular disease and prior fractures. The weakness of our study may rely on the evaluation of AAC with standard radiographs, as radiographs are less sensitive than other methods like computed tomography (CT) that may detect smaller calcifications. Using quantitative CT, AAC may be evaluated with the Agatston score that relies on the calcic density of the vascular wall, giving a more precise evaluation than standard radiographs. This method, however, delivers more radiation, is more expensive and more difficult to use in daily practice. We have also reported that the severity of AAC is positively associated with vertebral fracture in older men [15]. Prospective studies confirm the association between baseline AAC severity and prospectively assessed fracture risk in both sexes [3]. In the present study, women presented low Kauppila scores, and a mild aggravation on 17 years of follow-up. Women included here might not be a representative sample to study the association of cardiovascular events with fracture. We have also to consider that the serum concentration of these three miRNAs might not adequately reflect miRNA-induced epigenetic regulation taking place at cellular level in bone and vascular wall [55]. Although serum utilization is suitable for clinical research, miRNA secreted by cells and tissue microenvironment induce changes in miRNA profiling that are confined to extracellular vesicles such as exosomes and lipoproteins, when released into the blood stream [55,56]. Subtle modification within the bulk of miRNAs might be difficult to assess from an analytical point of view, limiting use in clinical settings.

In conclusion, serum concentrations of three selected miRNAs, miR-26a-5p, -34-5p and -223-5p were not associated with incident fractures nor with AAC aggravation in a large sample of women from the OFELY cohort. These miRNAs are unlikely to become biomarkers of clinical use.

Author Contributions

Conceptualization: Martine Croset, Pawel Szulc, Elisabeth Sornay Rendu, Roland Chapurlat.

Data curation: Marie-Eva Pickering, Marjorie Millet, Martine Croset, Olivier Borel, Elisabeth Sornay Rendu, Roland Chapurlat.

Investigation: Marie-Eva Pickering, Marjorie Millet, Jean-Charles Rousseau, Martine Croset, Roland Chapurlat.

Methodology: Pawel Szulc, Elisabeth Sornay Rendu, Roland Chapurlat.

Project administration: Roland Chapurlat.

Supervision: Roland Chapurlat.

Validation: Jean-Charles Rousseau, Roland Chapurlat.

Visualization: Elisabeth Sornay Rendu.

Writing – original draft: Marie-Eva Pickering.

Writing – review & editing: Marjorie Millet, Jean-Charles Rousseau, Martine Croset, Pawel Szulc, Elisabeth Sornay Rendu, Roland Chapurlat.

References

1. McFarlane SI, Muniyappa R, Shin JJ, Bahtiyar G, Sowers JR. Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? *Endocrine*. 2004 Feb; 23(1):1–10. <https://doi.org/10.1385/ENDO:23:1:01> PMID: 15034190
2. Laroche M, Pécourneau V, Blain H, Breuil V, Chapurlat R, Cortet B, et al. Osteoporosis and ischemic cardiovascular disease. *Jt Bone Spine Rev Rhum*. 2017 Jul; 84(4):427–32.
3. Szulc P. Vascular calcification and fracture risk. *Clin Cases Miner Bone Metab Off J Ital Soc Osteoporos Miner Metab Skelet Dis*. 2015 Aug; 12(2):139–41.
4. Rodondi N, Taylor BC, Bauer DC, Lui L-Y, Vogt MT, Fink HA, et al. Association between aortic calcification and total and cardiovascular mortality in older women. *J Intern Med*. 2007 Mar; 261(3):238–44. <https://doi.org/10.1111/j.1365-2796.2007.01769.x> PMID: 17305646
5. Bagger YZ, Tankó LB, Alexandersen P, Qin G, Christiansen C, Prospective Epidemiological Risk Factors Study Group. Radiographic measure of aorta calcification is a site-specific predictor of bone loss and fracture risk at the hip. *J Intern Med*. 2006 Jun; 259(6):598–605. <https://doi.org/10.1111/j.1365-2796.2006.01640.x> PMID: 16704561
6. Szulc P. Abdominal aortic calcification: A reappraisal of epidemiological and pathophysiological data. *Bone*. 2016 Mar; 84:25–37. <https://doi.org/10.1016/j.bone.2015.12.004> PMID: 26688274
7. Wilson PW, Kauppila LI, O'Donnell CJ, Kiel DP, Hannan M, Polak JM, et al. Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. *Circulation*. 2001 Mar 20; 103(11):1529–34. PMID: 11257080
8. Schousboe JT, Wilson KE, Kiel DP. Detection of abdominal aortic calcification with lateral spine imaging using DXA. *J Clin Densitom Off J Int Soc Clin Densitom*. 2006 Sep; 9(3):302–8.
9. Thompson B, Towler DA. Arterial calcification and bone physiology: role of the bone-vascular axis. *Nat Rev Endocrinol*. 2012 Sep; 8(9):529–43. <https://doi.org/10.1038/nrendo.2012.36> PMID: 22473330
10. Persy V D'Haese P. Vascular calcification and bone disease: the calcification paradox. *Trends Mol Med*. 2009 Sep; 15(9):405–16. <https://doi.org/10.1016/j.molmed.2009.07.001> PMID: 19733120
11. Maghraoui AE, Rezqi A, Mounach A, Achemlal L, Bezza A, Ghazlani I. Relationship between vertebral fracture prevalence and abdominal aortic calcification in men. *Rheumatology*. 2012 Jan 9; 51(9):1714–20. <https://doi.org/10.1093/rheumatology/kes126> PMID: 22661554
12. Kiel DP, Kauppila LI, Cupples LA, Hannan MT, O'Donnell CJ, Wilson PW. Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. *Calcif Tissue Int*. 2001 May; 68(5):271–6. PMID: 11683533
13. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V. Aortic Calcification and the Risk of Osteoporosis and Fractures. *J Clin Endocrinol Metab*. 2004 Sep 1; 89(9):4246–53. <https://doi.org/10.1210/jc.2003-030964> PMID: 15356016
14. Simon S, Fodor D, Muntean L, Poanta L, Cristea P, Rednic S. Bone mineral density, vertebral fractures and body mass index in postmenopausal women with abdominal aortic calcification. *Endocr Res*. 2014 février; 39(1):1–6. <https://doi.org/10.3109/07435800.2013.794425> PMID: 23650982

15. Szulc P, Samelson EJ, Sornay-Rendu E, Chapurlat R, Kiel DP. Severity of aortic calcification is positively associated with vertebral fracture in older men—a densitometry study in the STRAMBO cohort. *Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA*. 2013 Apr; 24(4):1177–84.
16. Kim KJ, Kim KM, Park KH, Choi HS, Rhee Y, Lee YH, et al. Aortic Calcification and Bone Metabolism: The Relationship between Aortic Calcification, BMD, Vertebral Fracture, 25-Hydroxyvitamin D, and Osteocalcin. *Calcif Tissue Int*. 2012 Sep 29; 91(6):370–8. <https://doi.org/10.1007/s00223-012-9642-1> PMID: 23052223
17. Bartel DP. Metazoan MicroRNAs. *Cell*. 2018 Mar 22; 173(1):20–51. <https://doi.org/10.1016/j.cell.2018.03.006> PMID: 29570994
18. Garmilla-Ezquerria P, Sañudo C, Delgado-Calle J, Pérez-Núñez MI, Sumillera M, Riancho JA. Analysis of the bone microRNome in osteoporotic fractures. *Calcif Tissue Int*. 2015 Jan; 96(1):30–7. <https://doi.org/10.1007/s00223-014-9935-7> PMID: 25432767
19. van Wijnen AJ, van de Peppel J, van Leeuwen JP, Lian JB, Stein GS, Westendorf JJ, et al. MicroRNA functions in osteogenesis and dysfunctions in osteoporosis. *Curr Osteoporos Rep*. 2013 Jun; 11(2):72–82. <https://doi.org/10.1007/s11914-013-0143-6> PMID: 23605904
20. Gurha P. MicroRNAs in cardiovascular disease. *Curr Opin Cardiol*. 2016 May; 31(3):249–54. <https://doi.org/10.1097/HCO.0000000000000280> PMID: 26885771
21. Lee S, Choi E, Kim S-M, Hwang K-C. MicroRNAs as mediators of cardiovascular disease: Targets to be manipulated. *World J Biol Chem*. 2015 May 26; 6(2):34–8. <https://doi.org/10.4331/wjbc.v6.i2.34> PMID: 26009702
22. Leopold JA. MicroRNAs Regulate Vascular Medial Calcification. *Cells*. 2014 Oct 14; 3(4):963–80. <https://doi.org/10.3390/cells3040963> PMID: 25317928
23. Alkagiet S, Tziomalos K. Vascular calcification: the role of microRNAs. *Biomol Concepts*. 2017 May 24; 8(2):119–23. <https://doi.org/10.1515/bmc-2017-0001> PMID: 28426428
24. Yavropoulou MP, Anastasilakis AD, Makras P, Tsalikakis DG, Grammatiki M, Yovos JG. Expression of microRNAs that regulate bone turnover in the serum of postmenopausal women with low bone mass and vertebral fractures. *Eur J Endocrinol*. 2017 Feb; 176(2):169–76. <https://doi.org/10.1530/EJE-16-0583> PMID: 27836951
25. Panach L, Mifsut D, Tarín JJ, Cano A, García-Pérez MÁ. Serum Circulating MicroRNAs as Biomarkers of Osteoporotic Fracture. *Calcif Tissue Int*. 2015 Nov; 97(5):495–505. <https://doi.org/10.1007/s00223-015-0036-z> PMID: 26163235
26. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. *Trends Mol Med*. 2014 Aug; 20(8):460–9. <https://doi.org/10.1016/j.molmed.2014.06.005> PMID: 25027972
27. Balzano F, Deiana M, Dei Giudici S, Oggiano A, Baralla A, Pasella S, et al. miRNA Stability in Frozen Plasma Samples. *Mol Basel Switz*. 2015 Oct 20; 20(10):19030–40.
28. Arlot ME, Sornay-Rendu E, Garnero P, Vey-Marty B, Delmas PD. Apparent pre- and postmenopausal bone loss evaluated by DXA at different skeletal sites in women: the OFELY cohort. *J Bone Miner Res Off J Am Soc Bone Miner Res*. 1997 Apr; 12(4):683–90.
29. Albrand G, Munoz F, Sornay-Rendu E, DuBoeuf F, Delmas PD. Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study. *Bone*. 2003 Jan; 32(1):78–85. PMID: 12584039
30. Schoppet M, Rauner M, Benner J, Chapurlat R, Hofbauer LC, Szulc P. Serum fetuin-A levels and abdominal aortic calcification in healthy men—The STRAMBO study. *Bone*. 2015 Oct; 79:196–202. <https://doi.org/10.1016/j.bone.2015.06.004> PMID: 26079998
31. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. *J Bone Miner Res*. 1993 Sep 1; 8(9):1137–48. <https://doi.org/10.1002/jbmr.5650080915> PMID: 8237484
32. Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. *Atherosclerosis*. 1997 Jul 25; 132(2):245–50. PMID: 9242971
33. Sugatani T, Hruska KA. MicroRNA-223 is a key factor in osteoclast differentiation. *J Cell Biochem*. 2007 Jul 1; 101(4):996–9. <https://doi.org/10.1002/jcb.21335> PMID: 17471500
34. Wu W, Shang YQ, Dai SL, Yi F, Wang XC. MiR-26a regulates vascular smooth muscle cell calcification in vitro through targeting CTGF. *Bratisl Lek Listy*. 2017; 118(8):499–503. https://doi.org/10.4149/BLL_2017_096 PMID: 29050490
35. Icli B, Wara AKM, Mosehi J, Sun X, Plovie E, Cahill M, et al. MicroRNA-26a Regulates Pathological and Physiological Angiogenesis by Targeting BMP/SMAD1 Signaling Novelty and Significance. *Circ Res*. 2013 Nov 8; 113(11):1231–41.

36. Icli B, Nabzdyk CS, Lujan-Hernandez J, Cahill M, Auster ME, Wara AKM, et al. Regulation of impaired angiogenesis in diabetic dermal wound healing by microRNA-26a. *J Mol Cell Cardiol.* 2016 Feb; 91:151–9. <https://doi.org/10.1016/j.yjmcc.2016.01.007> PMID: 26776318
37. Icli B, Dorbala P, Feinberg MW. An emerging role for the miR-26 family in cardiovascular disease. *Trends Cardiovasc Med.* 2014 Aug; 24(6):241. <https://doi.org/10.1016/j.tcm.2014.06.003> PMID: 25066487
38. Krzeszinska JY, Wei W, Huynh H, Jin Z, Wang X, Chang T-C, et al. miR-34a Blocks Osteoporosis and Bone Metastasis by Inhibiting Osteoclastogenesis and Tgif2. *Nature.* 2014 Aug 28; 512(7515):431. <https://doi.org/10.1038/nature13375> PMID: 25043055
39. Concepcion CP, Han Y-C, Mu P, Bonetti C, Yao E, D'Andrea A, et al. Intact p53-Dependent Responses in miR-34–Deficient Mice. *PLoS Genet* [Internet]. 2012 Jul; 8(7). Available from: <https://www.ncbi.nlm.nih.gov/gate2.inist.fr/pmc/articles/PMC3406012/>
40. Chen L, Holmstrøm K, Qiu W, Ditzel N, Shi K, Hokland L, et al. MicroRNA-34a Inhibits Osteoblast Differentiation and In Vivo Bone Formation of Human Stromal Stem Cells. *STEM CELLS.* 2014 Apr 1; 32(4):902–12. <https://doi.org/10.1002/stem.1615> PMID: 24307639
41. Boon RA, Iekushi K, Lechner S, Seeger T, Fischer A, Heydt S, et al. MicroRNA-34a regulates cardiac ageing and function. *Nature.* 2013 Mar; 495(7439):107–10. <https://doi.org/10.1038/nature11919> PMID: 23426265
42. Taïbi F, Metzinger-Le Meuth V, Massy ZA, Metzinger L. miR-223: An inflammatory oncomiR enters the cardiovascular field. *Biochim Biophys Acta.* 2014 Jul; 1842(7):1001–9. <https://doi.org/10.1016/j.bbadis.2014.03.005> PMID: 24657505
43. Shan Z, Qin S, Li W, Wu W, Yang J, Chu M, et al. An Endocrine Genetic Signal Between Blood Cells and Vascular Smooth Muscle Cells: Role of MicroRNA-223 in Smooth Muscle Function and Atherogenesis. *J Am Coll Cardiol.* 2015 Jun 16; 65(23):2526–37. <https://doi.org/10.1016/j.jacc.2015.03.570> PMID: 26065992
44. Vickers KC, Landstreet SR, Levin MG, Shoucri BM, Toth CL, Taylor RC, et al. MicroRNA-223 coordinates cholesterol homeostasis. *Proc Natl Acad Sci U S A.* 2014 Oct 7; 111(40):14518–23. <https://doi.org/10.1073/pnas.1215767111> PMID: 25246565
45. Chu M, Wu R, Qin S, Hua W, Shan Z, Rong X, et al. Bone Marrow-Derived MicroRNA-223 Works as an Endocrine Genetic Signal in Vascular Endothelial Cells and Participates in Vascular Injury From Kawasaki Disease. *J Am Heart Assoc.* 2017 Feb 14; 6(2).
46. M'Baya-Moutoula E, Louvet L, Metzinger-Le Meuth V, Massy ZA, Metzinger L. High inorganic phosphate concentration inhibits osteoclastogenesis by modulating miR-223. *Biochim Biophys Acta.* 2015 Oct; 1852(10 Pt A):2202–12. <https://doi.org/10.1016/j.bbadis.2015.08.003> PMID: 26255635
47. Ulbing M, Kirsch AH, Leber B, Lemesch S, Münzker J, Schweighofer N, et al. MicroRNAs 223-3p and 93-5p in patients with chronic kidney disease before and after renal transplantation. *Bone.* 2017; 95:115–23. <https://doi.org/10.1016/j.bone.2016.11.016> PMID: 27866993
48. Croset M, Goehrig D, Frackowiak A, Bonnelye E, Ansieau S, Puisieux A, et al. TWIST1 expression in breast cancer cells facilitates bone metastasis formation. *J Bone Miner Res Off J Am Soc Bone Miner Res.* 2014 Aug; 29(8):1886–99.
49. Szulc P, Chapurlat R, Hofbauer LC. Prediction of Fractures and Major Cardiovascular Events in Men Using Serum Osteoprotegerin Levels: The Prospective STRAMBO Study. *J Bone Miner Res Off J Am Soc Bone Miner Res.* 2017 Nov; 32(11):2288–96.
50. Rajzbaum G, Roger VL, Bézie Y, Chauffert M, Bréville P, Roux F, et al. French women, fractures and aortic calcifications. *J Intern Med.* 2005 Jan; 257(1):117–9. <https://doi.org/10.1111/j.1365-2796.2004.01430.x> PMID: 15606383
51. Hanna TN, Zygmunt ME, Harmouche E, Salastekar N, Johnson J-O, Khosa F. Association of lumbar fractures, abdominal aortic calcification, and osteopenia. *Clin Imaging.* 2015 Jul 1; 39(4):662–6. <https://doi.org/10.1016/j.clinimag.2014.11.021> PMID: 25537431
52. Zhou R, Zhou H, Cui M, Chen L, Xu J. The Association between Aortic Calcification and Fracture Risk in Postmenopausal Women in China: The Prospective Chongqing Osteoporosis Study. *PLoS ONE* [Internet]. 2014 May 9; 9(5). Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015900/>
53. El Maghraoui A, Hamza T, Sadni S, El Maataoui A, Majjad A, Rezqi A, et al. Vitamin D status and abdominal aortic calcification in postmenopausal women. *J Bone Miner Metab.* 2018 Mar; 36(2):229–37. <https://doi.org/10.1007/s00774-017-0832-9> PMID: 28364325
54. Feichtinger X, Muschitz C, Heimeil P, Baierl A, Fahrleitner-Pammer A, Redl H, et al. Bone-related Circulating MicroRNAs miR-29b-3p, miR-550a-3p, and miR-324-3p and their Association to Bone Microstructure and Histomorphometry. *Sci Rep.* 2018 Mar 20; 8(1):4867. <https://doi.org/10.1038/s41598-018-22844-2> PMID: 29559644

55. Hackl M, Heilmeier U, Weilner S, Grillari J. Circulating microRNAs as novel biomarkers for bone diseases—Complex signatures for multifactorial diseases? *Mol Cell Endocrinol*. 2016 05; 432:83–95. <https://doi.org/10.1016/j.mce.2015.10.015> PMID: [26525415](https://pubmed.ncbi.nlm.nih.gov/26525415/)
56. Sempere LF, Keto J, Fabbri M. Exosomal MicroRNAs in Breast Cancer towards Diagnostic and Therapeutic Applications. *Cancers*. 2017 Jun 24; 9(7).